SCHEMBL5451228

SCHEMBL5451228

Cc1ccc(NC(=O)Nc2sc3c(c2C(N)=O)CCOC3)cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.61
FLT3 P36888 1/20 0.53
KCNH2 Q12809 7/20 0.51
ANO1 Q5XXA6 4/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
EPHB4 P54760 1/20 0.49
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
ATM Q13315 1/20 0.48
CXCR2 P25025 1/20 0.48
TNIK Q9UKE5 1/20 0.48
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
PTPRC P08575 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461010 0.91 CFTR (0.58) CFTRFLT3KCNH2ANO1MEN1
SCHEMBL5449304 0.88 CFTR (0.65) CFTRFLT3KCNH2ANO1MEN1
SCHEMBL5451169 0.88 CFTR (0.55) CFTRFLT3KCNH2ANO1MEN1
SCHEMBL5451652 0.87 CFTR (0.60) CFTRFLT3KCNH2ANO1MEN1
SCHEMBL5450806 0.86 CFTR (0.57) CFTRKCNH2ANO1MEN1KMT2A
SCHEMBL5454317 0.85 MEN1 (0.63) CFTRKCNH2ANO1MEN1KMT2A
SCHEMBL16962264 0.85 KCNH2 (0.68) CFTRFLT3KCNH2ANO1MEN1
SCHEMBL5459139 0.84 CFTR (0.60) CFTRFLT3KCNH2ANO1MEN1
SCHEMBL5446242 0.84 CFTR (0.55) CFTRFLT3KCNH2ANO1MEN1
SCHEMBL5446177 0.84 CFTR (0.60) CFTRFLT3KCNH2ANO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885FLT3 3509/4885KCNH2 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.